Muscle & Nerve · 2021 · 38 citations · 10 references
MedicineRehabilitation MedicineHealth AssessmentPsychometricsRehabilitationDisability EvaluationHealth-related Quality Of Life MeasurementNeuromuscular RehabilitationSymptom Burden AssessmentDisease Burden AnalysisFunctional Rating ScalesInternal Consistency ReliabilityPatient-reported Outcome MeasurementPatient-reported Symptom BurdenSelf-reported Symptom BurdenTest-retest ReliabilityValidity Testing
INTRODUCTION: The Spinal Muscular Atrophy Health Index (SMA-HI) is a multifaceted, disease-specific, patient-reported outcome to measure an SMA patient's perception of their disease burden. In preparation for upcoming therapeutic trials, we examine the validity, reliability, and usability of the SMA-HI in adults, teenagers, and children with SMA. METHODS: Using data from a cross-sectional study of 359 international adult patients with SMA, we identified the most relevant symptoms to include in the SMA-HI. We utilized factor analysis, patient interviews with adults and minors (age 8-15 years), known-group validity testing, and test-retest reliability assessments to evaluate and refine the SMA-HI. RESULTS: The SMA-HI measures overall disease burden and 15 areas of SMA health. Fifteen adult patients and five patients, age 8 to 15 years, participated in semistructured qualitative interviews and found the SMA-HI to be comprehensive, easily completed, and to have clear meaning. The final SMA-HI and its subscales demonstrated good internal consistency (Cronbach α = 0.77-0.96), high test-retest reliability (intraclass correlation coefficient = 0.60-0.96), and an ability to differentiate between SMA groups with different disease severities affecting areas such as employment and ambulation (P < .0001 for both). DISCUSSION: This research provides evidence that the SMA-HI is a valid, relevant, and reliable outcome measure to assess multifaceted patient-reported disease burden in older children, teenagers, and adults with SMA. The SMA-HI provides an opportunity for researchers and clinicians to measure a SMA patient's perception of their health and determine relevant changes in response to therapeutic intervention or disease progression.
10
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Jerry R. Mendell, Samiah Al-Zaidy, Richard Shell et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text
Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q
Judith Melki, Sonia Abdelhak, P. Sheth et al. · Nature · 1990 · 399 citations
Population-based analysis of survival in spinal muscular atrophy
Camiel A. Wijngaarde, Marloes Stam, Louise Otto et al. · Neurology · 2020 · 105 citations